Phase 2/3 CARDINAL trial of bardoxolone methyl in patients with CKD caused by Alport syndrome

Reata is currently enrolling patients in the Phase 3 portion of its Phase 2/3 CARDINAL trial of bardoxolone methyl in patients with CKD caused by Alport syndrome.